Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
5 Most Active Penny Stocks Today & Why They're Moving Now
02:11pm, Wednesday, 01'st Nov 2023
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Outlook Therapeutics® to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference
08:05am, Wednesday, 01'st Nov 2023
Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET
Best Penny Stocks Under $1? 4 To Watch This Week
10:32am, Thursday, 19'th Oct 2023
What are the best penny stocks under $1? If you saw this headline, that's probably a question you have heading into the second half of the week.
4 Top Penny Stocks To Buy For Under $5
03:33pm, Wednesday, 18'th Oct 2023
Looking at the stock market today is like watching an action movie. One minute the bulls are stampeding and stocks are rising.
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
08:05am, Thursday, 21'st Sep 2023
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:05am, Tuesday, 05'th Sep 2023
Live video webcast presentation on Wednesday, September 13th at 9:30 AM ET Live video webcast presentation on Wednesday, September 13th at 9:30 AM ET
Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today?
08:16am, Wednesday, 30'th Aug 2023
Outlook Therapeutics (NASDAQ: OTLK ) stock is taking a beating on Wednesday after getting a rejection letter from the FDA. That letter has to do with its biologics license application (BLA) for ONS-5
Outlook Therapeutics collapses as FDA rejects application for eye drug
07:16am, Wednesday, 30'th Aug 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) stock collapsed, losing some 70% of its value in premarket, after the drug discovery firm's potential treatment for eye disease was rejected by the US Food and D
US FDA declines to approve Outlook Therapeutics' eye disease drug
06:35am, Wednesday, 30'th Aug 2023
Outlook Therapeutics said on Wednesday the U.S. Food and Drug Administration declined to approve its experimental eye disease drug, in part due to manufacturing issues observed during pre-approval ins
Outlook Therapeutics' stock tumbles 71% premarket after FDA rejects treatment for wet AMD
06:29am, Wednesday, 30'th Aug 2023
Outlook Therapeutics Inc.'s stock OTLK, +10.16% tumbled 71% in premarket trade Wednesday, after the company said the U.S. Food and Drug Administration has issued a Control Response Letter for the comp
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
11:39am, Monday, 14'th Aug 2023
Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
08:45am, Tuesday, 01'st Aug 2023
ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevac
Outlook Therapeutics: August PDUFA May Be A Buy With Some Caveats
01:06am, Saturday, 10'th Jun 2023
OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's also positive data. However, certain developments stop me from being overly enthusiastic.
Why Shares of Outlook Therapeutics Rose Tuesday
01:59pm, Tuesday, 06'th Jun 2023
Outlook, a clinical-stage biotech, is awaiting potential approval for a wet AMD therapy. The therapy has a PDUFA date of Aug. 29 from the FDA.
Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?
11:01am, Thursday, 25'th May 2023
From a technical perspective, Oncobiologics, Inc. (OTLK) is looking like an interesting pick, as it just reached a key level of support. OTLK's 50-day simple moving average crossed above its 200-day s
